The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.    Read More

Following are the week’s biggest winners and losers. Find out why shares of Valero and Lehman popped while State Street and Wynn dropped.   Read More

Following are the day’s biggest winners and losers. Find out why shares of Smithfield Foods and Compuware popped while Manitowoc and Las Vegas Sands dropped.   Read More

Billionaire Alfred Mann must not have liked watching stock in the company bearing his name fall to another new low today in the wake of Eli Lilly giving up on inhaled insulin.    Read More

I thought I was finished with the post-Pfizer analyst meeting reaction with yesterday's post, but when an extraordinarily bearish 77-page research note from Credit Suisse big pharma analyst Catherine Arnold arrived in my inbox this morning, I had to do one more installment. She thinks Pfizer should buy Wyeth or Amgen...   Read More

Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.    Read More

If or when you watch one of the presidential  debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements...   Read More